Medicare GLP-1 pilot shelved

The Trump administration has indefinitely delayed a Medicare pilot that was supposed to expand coverage of GLP-1 weight-loss drugs for older patients. (axios.com) Federal officials told Axios the pilot was paused after health insurers raised concerns about participating, even though the Centers for Medicare & Medicaid Services had already set up a short-term “Medicare GLP-1 Bridge” running from July 1, 2026, through December 31, 2027. (axios.com) (cms.gov) GLP-1 drugs mimic a gut hormone that helps control blood sugar and appetite; brand names in the Medicare debate include Wegovy, Zepbound, Ozempic and Mounjaro. The White House said in November 2025 that deals with Eli Lilly and Novo Nordisk would cut Medicare prices for those medicines to $245, with a $50 monthly beneficiary co-pay. (whitehouse.gov) (cnbc.com) That promise mattered because Medicare has long barred routine Part D coverage of drugs used only for weight loss. In April 2025, the administration also scrapped a Biden-era proposal that would have reinterpreted the law to allow broader Medicare coverage of anti-obesity medicines. (axios.com) (cms.gov) Instead of changing the statute, the administration turned to a demonstration model through the Centers for Medicare & Medicaid Services Innovation Center. CMS announced the voluntary BALANCE model on December 23, 2025, saying it would let Medicare Part D plans and state Medicaid agencies cover select GLP-1 drugs while CMS negotiated pricing terms. (cms.gov 1) (cms.gov 2) CMS was still encouraging Medicare Part D sponsors and state Medicaid agencies to apply for that model as recently as March 9, 2026. A related request for applications said the Medicare Part D portion was slated to begin in January 2027, after Medicaid starts in May 2026. (cms.gov 1) (cms.gov 2) The delay leaves a narrower bridge in place but clouds the longer-term path for seniors who expected broader access after Trump’s November announcement. Axios reported that senior administration officials had said about 10% of Medicare enrollees would become newly eligible under the earlier deal. (cms.gov) (axios.com) Insurers had warned for months that covering obesity drugs at scale could carry a large federal price tag, while manufacturers and obesity-treatment advocates argued lower negotiated prices could make coverage workable. Congress remains the clearest route to a permanent Medicare benefit, but no new law has passed. (axios.com) (cms.gov) For now, Medicare patients can see a temporary bridge on paper and a shelved pilot in practice — a much smaller opening than the administration advertised five months ago. (cms.gov) (axios.com)